Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Research

Expression of hypoxia-related markers in inflammatory myofibroblastic tumors of the head and neck

Authors: Kui-Rong Wang, Tao Jiang, Ting-Ting Wu, Shui-Hong Zhou, Hong-Tian Yao, Qin-Ying Wang, Zhong-Jie Lu

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Background

The etiology of inflammatory myofibroblastic tumors (IMTs) is controversial and the prognosis is unpredictable. Previous studies have not investigated the expression of hypoxia-related markers in IMTs.

Methods

Between 2002 and 2012, 12 consecutive patients with histologically proven IMTs were enrolled in the study. Immunohistochemistry was used to detect GLUT-1, HIF-1α, PI3K, and p-Akt expression in paraffin-embedded tumor specimens. Associations among GLUT-1, HIF-1α, PI3K, and p-Akt protein expression and clinical parameters were investigated.

Results

The mean duration of follow-up was 52.1 months (range, 11 to 132 months). Six patients had local recurrence. GLUT-1, HIF-1α, PI3K, and p-Akt expression were detected in 41.7%, 50.0%, 33.3%, and 41.7% of patients, respectively. Fisher’s exact test revealed significant correlations between recurrence of IMT and PI3K expression (P = 0.01) and p-Akt expression (P = 0.015). Univariate analyses revealed significant correlations between survival and GLUT-1 expression (P = 0.028), PI3K expression (P = 0.006), and p-Akt expression (P = 0.028). Multivariate analysis did not show a significant relationship between survival and GLUT-1, HIF-1α, PI3K, or p-Akt. Spearman rank correlation analysis showed significant correlations between HIF-1α and PI3K expression (r = 0.707, P = 0.01) and between p-Akt and PI3K expression (r = 0.837, P = 0.001).

Conclusions

Although our results are inconclusive owing to the small sample size, they suggest that PI3K and p-Akt expression may play a role in the recurrence of IMTs of the head and neck.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissues and Bone. 2002, Lyon: IARC Press, 91-93. Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissues and Bone. 2002, Lyon: IARC Press, 91-93.
2.
go back to reference Ong HS, Ji T, Zhang CP, Li J, Wang LZ, Li RR, Sun J, Ma CY: Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features. Oral Oncol. 2012, 48: 141-148. 10.1016/j.oraloncology.2011.09.004.CrossRefPubMed Ong HS, Ji T, Zhang CP, Li J, Wang LZ, Li RR, Sun J, Ma CY: Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features. Oral Oncol. 2012, 48: 141-148. 10.1016/j.oraloncology.2011.09.004.CrossRefPubMed
3.
go back to reference Jiang YH, Cheng B, Ge MH, Cheng Y, Zhang G: Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastictumours. J Int Med Res. 2009, 37: 867-877. 10.1177/147323000903700332.CrossRefPubMed Jiang YH, Cheng B, Ge MH, Cheng Y, Zhang G: Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastictumours. J Int Med Res. 2009, 37: 867-877. 10.1177/147323000903700332.CrossRefPubMed
4.
go back to reference Coffin CM, Hornick JL, Fletcher CD: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J SurgPathol. 2007, 31: 509-520.CrossRef Coffin CM, Hornick JL, Fletcher CD: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J SurgPathol. 2007, 31: 509-520.CrossRef
5.
go back to reference Lacoste L, Galant C, Gigot JF, Lacoste B, Annet L: Inflammatory myofibroblastic tumor of the pancreatic head. JBR-BTR. 2012, 95: 267-269.PubMed Lacoste L, Galant C, Gigot JF, Lacoste B, Annet L: Inflammatory myofibroblastic tumor of the pancreatic head. JBR-BTR. 2012, 95: 267-269.PubMed
6.
go back to reference Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J: The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor. Mol Imaging Biol. 2004, 6: 126-130. 10.1016/j.mibio.2004.03.003.CrossRefPubMed Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J: The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor. Mol Imaging Biol. 2004, 6: 126-130. 10.1016/j.mibio.2004.03.003.CrossRefPubMed
7.
go back to reference Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY: Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2012, 34: 1395-1402. 10.1002/hed.21945.CrossRefPubMed Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY: Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2012, 34: 1395-1402. 10.1002/hed.21945.CrossRefPubMed
8.
go back to reference Nagamatsu A, Umesaki N, Li L, Tanaka T: Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010, 23: 1069-1076.PubMed Nagamatsu A, Umesaki N, Li L, Tanaka T: Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010, 23: 1069-1076.PubMed
9.
go back to reference Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011, 11: 167-10.1186/1471-2407-11-167.PubMedCentralCrossRefPubMed Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011, 11: 167-10.1186/1471-2407-11-167.PubMedCentralCrossRefPubMed
10.
go back to reference Taddei ML, Giannoni E, Comito G, Chiarugi P: Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013, 341: 80-96. 10.1016/j.canlet.2013.01.042.CrossRefPubMed Taddei ML, Giannoni E, Comito G, Chiarugi P: Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013, 341: 80-96. 10.1016/j.canlet.2013.01.042.CrossRefPubMed
11.
go back to reference Cannito S, Novo E, Compagnone A, Valfrè Di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S, Parola M: Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 2008, 29: 2267-2278. 10.1093/carcin/bgn216.CrossRefPubMed Cannito S, Novo E, Compagnone A, Valfrè Di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S, Parola M: Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 2008, 29: 2267-2278. 10.1093/carcin/bgn216.CrossRefPubMed
12.
go back to reference Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH: Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. OncolLett. 2013, 5: 261-266. Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH: Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. OncolLett. 2013, 5: 261-266.
13.
go back to reference André H, Pereira TS: Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1α. J BiolChem. 2008, 283: 29375-29384. André H, Pereira TS: Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1α. J BiolChem. 2008, 283: 29375-29384.
14.
15.
go back to reference Zheng Y, Ni Y, Huang X, Wang Z, Han W: Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. OncolLett. 2013, 5: 1285-1289. Zheng Y, Ni Y, Huang X, Wang Z, Han W: Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. OncolLett. 2013, 5: 1285-1289.
16.
go back to reference Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, Kanai Y, Hiraoka N: Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013, 8: e55146-10.1371/journal.pone.0055146.PubMedCentralCrossRefPubMed Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, Kanai Y, Hiraoka N: Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013, 8: e55146-10.1371/journal.pone.0055146.PubMedCentralCrossRefPubMed
17.
go back to reference Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J: The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009, 8: 947-958. 10.1158/1535-7163.MCT-08-0981.PubMedCentralCrossRefPubMed Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J: The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009, 8: 947-958. 10.1158/1535-7163.MCT-08-0981.PubMedCentralCrossRefPubMed
18.
go back to reference Zhu H, Feng Y, Zhang J, Zhou X, Hao B, Zhang G, Shi R: Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma. Cancer BiolTher. 2011, 11: 981-987. Zhu H, Feng Y, Zhang J, Zhou X, Hao B, Zhang G, Shi R: Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma. Cancer BiolTher. 2011, 11: 981-987.
19.
go back to reference Agani F, Jiang BH: Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTORpathway in cancer. Curr Cancer Drug Targets. 2013, 13: 245-251. 10.2174/1568009611313030003.CrossRefPubMed Agani F, Jiang BH: Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTORpathway in cancer. Curr Cancer Drug Targets. 2013, 13: 245-251. 10.2174/1568009611313030003.CrossRefPubMed
20.
go back to reference Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008, 37: 426-431. 10.1097/MPA.0b013e3181735ccb.CrossRefPubMed Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008, 37: 426-431. 10.1097/MPA.0b013e3181735ccb.CrossRefPubMed
21.
go back to reference Chen YF, Zhang WD, Wu MW, Ou-Yang D, Zhang Q: Inflammatory myofibroblastic tumor of the head and neck. Med Oncol. 2011, 28 (Suppl 1): S349-S353.CrossRefPubMed Chen YF, Zhang WD, Wu MW, Ou-Yang D, Zhang Q: Inflammatory myofibroblastic tumor of the head and neck. Med Oncol. 2011, 28 (Suppl 1): S349-S353.CrossRefPubMed
22.
go back to reference Shen WQ, Cheng KJ, Bao YY, Zhou SH, Yao HT: Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of ceruminous adenoma. Head Neck Oncol. 2012, 4: 18-10.1186/1758-3284-4-18.PubMedCentralCrossRefPubMed Shen WQ, Cheng KJ, Bao YY, Zhou SH, Yao HT: Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of ceruminous adenoma. Head Neck Oncol. 2012, 4: 18-10.1186/1758-3284-4-18.PubMedCentralCrossRefPubMed
23.
go back to reference Fang J, Bao YY, Zhou SH, Luo XM, Yao HT, He JF, Wang QY: Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: clinicopathological features and biomarkers of adenoid cystic carcinoma. OncolLett. 2012, 4: 1234-1240. Fang J, Bao YY, Zhou SH, Luo XM, Yao HT, He JF, Wang QY: Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: clinicopathological features and biomarkers of adenoid cystic carcinoma. OncolLett. 2012, 4: 1234-1240.
24.
go back to reference Gort EH, Groot AJ, Derks Van De Ven TL, Van Der Groep P, Ver Laan I, Van Laar T, Van Diest PJ, van der Wall E, Shvarts A: Hypoxia-inducible factor-1a expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene. 2006, 25: 6123-6127. 10.1038/sj.onc.1209643.CrossRefPubMed Gort EH, Groot AJ, Derks Van De Ven TL, Van Der Groep P, Ver Laan I, Van Laar T, Van Diest PJ, van der Wall E, Shvarts A: Hypoxia-inducible factor-1a expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene. 2006, 25: 6123-6127. 10.1038/sj.onc.1209643.CrossRefPubMed
25.
go back to reference Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009, 19: 12-16. 10.1016/j.semcancer.2008.11.009.CrossRefPubMed Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009, 19: 12-16. 10.1016/j.semcancer.2008.11.009.CrossRefPubMed
Metadata
Title
Expression of hypoxia-related markers in inflammatory myofibroblastic tumors of the head and neck
Authors
Kui-Rong Wang
Tao Jiang
Ting-Ting Wu
Shui-Hong Zhou
Hong-Tian Yao
Qin-Ying Wang
Zhong-Jie Lu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-294

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue